Case Report on Aseptic Abscess Syndrome and Treatment with Infliximab
Author Information
Author(s): Ucci Federica Maria, Scrivo Rossana, Alessandri Cristiano, Conti Fabrizio, Priori Roberta
Primary Institution: Sapienza University of Rome
Hypothesis
Can a patient with aseptic abscess syndrome achieve remission using both infliximab originator and biosimilar at varied intervals?
Conclusion
The patient achieved remission from aseptic abscess syndrome after treatment with both infliximab and a biosimilar, although requiring shortened infusion intervals.
Supporting Evidence
- The patient initially responded to glucocorticoids but experienced flares upon discontinuation.
- Remission was achieved with a biosimilar TNFα inhibitor after a non-medical switch.
- The case highlights the challenges in managing a rare condition with limited existing literature.
Takeaway
A woman with a rare disease called aseptic abscess syndrome got better after taking a medicine called infliximab, but she needed to take it more often than usual.
Methodology
The case report details the patient's medical history, treatment with glucocorticoids, and subsequent use of infliximab and a biosimilar.
Potential Biases
Potential bias due to the lack of control group and reliance on a single patient's experience.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 51-year-old woman with no significant medical history prior to the onset of symptoms.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website